Otsuka Looks To New Products As Abilify Plunge Bites
This article was originally published in PharmAsia News
Otsuka has added some flesh to the bones of its strategy to fill the hole left by plunging sales of mainstay product Abilify due to generic competition, with new formulations of the atypical antipsychotic and pipeline CNS drugs seen as driving growth over the next few years.
You may also be interested in...
Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.